-
2023-503797-21-00
5
2022-08-10
Metastatic Colorectal Cancer
-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2023-505441-69-00
5
2022-05-17
refractory, advanced gastro-oesophageal cancer
-
2024-511187-81-00
5
2022-03-28
Colorectal Cancer (CRC)
-
2023-505457-40-00
5
2022-02-02
Previously Untreated Advanced Gastric or Gastroesophageal Junction
Can
-
2023-506897-11-00
5
2021-10-18
Non-diabetic chronic kidney disease
-
2024-512717-41-00
4
2021-10-01
Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
-
2023-510230-84-00
5
2021-05-28
Severe asthma with an eosinophilic phenotype
-
2023-505273-33-00
5
2021-02-15
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial
(NTM
-
2024-511504-17-00
5
2020-12-15
Primary immune thrombocytopenia
-
2023-506435-15-00
3
2020-08-25
Prostate cancer
-
2023-506528-95-00
5
2019-11-21
Psoriatic Arthritis
-
2022-503050-39-00
5
2019-11-12
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
-
2024-511533-35-00
4
2018-09-03
Mantle Cell Lymphoma
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2024-512934-14-00
5
2016-11-07
advanced or metastatic adenocarcinoma of the stomach or gastroesophage
-
2024-511235-10-00
5
2016-07-25
Generalized mantle cell Lymphoma
-
2024-514515-10-00
5
2016-06-16
Breast Cancer
-
2024-516630-35-01
4
2015-01-12
NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS
-
2024-511639-83-00
9
2014-09-01
Anaplastic Large T-cell Lymphoma ALK negative
-
2023-507291-52-00
4
2014-03-24
Extranodal Marginal Zone Lymphoma
-
2023-507674-41-00
1
Advanced high-grade serous ovarian cancer (OC)
-
2024-512804-20-00
5
Metastatic Colorectal Cancer
-
2024-517445-13-00
4
Extended stage small cell lung cancer patients confirmed histologicall